Kris Vaddi

9.9k citations

68 papers · 3.7k indexed · 2 hit papers · h-index 26

Impact in

Genetics top 0.5%
- Myeloproliferative Neoplasms: Diagnosis and Treatment
Hematology top 1%
- Chronic Myeloid Leukemia Treatments
- Acute Myeloid Leukemia Research

Papers in

Genetics 23
- Myeloproliferative Neoplasms: Diagnosis and Treatment 22
Hematology 21
- Acute Myeloid Leukemia Research 10
- Chronic Myeloid Leukemia Treatments 7

Co-authors: Reid Huber Stuart P. Weisberg Jacob E. Lemieux Sarah Slaymaker Anthony W. Ferrante Israel Charo Deborah Hunter Rudolph L. Leibel
Journals: Blood (21 papers)Cancer Research (13 papers)Journal of Clinical Oncology (5 papers)Clinical Cancer Research (3 papers)Molecular Cancer Therapeutics (3 papers)
Partner nations: United States Italy Qatar

In The Last Decade

Kris Vaddi

65 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis 2010 · 847 citations

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if any of the following hold:

it has ≥500 total citations;
it reaches ≥1.5× the top-1% citation threshold for papers in the same subfield and year (the threshold is the minimum needed to enter the top 1%, not the average within it);
it reaches the top citation threshold in at least one of its specific research topics.

2010 New England Journal of Medicine
2005 Journal of Clinical Investigation

Peers

Countries citing papers authored by Kris Vaddi

Since Specialization

Citations

This map shows the geographic impact of Kris Vaddi's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Kris Vaddi with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Kris Vaddi more than expected).

Fields of papers citing papers by Kris Vaddi

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Kris Vaddi. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Kris Vaddi. The network helps show where Kris Vaddi may publish in the future.

Co-authors

The 25 scholars most cited alongside Kris Vaddi, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Kris Vaddi Line = papers co-authored together Kris Vaddi links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Targeting PRMT5 in Primary Hemophagocytic Lymphohistiocytosis: A Novel Therapeutic Approach Using a Perforin-Deficient Mouse Model Blood ·Sheldon Steyn, Chia-Jo Chen, Rachel Saadey, Charlene Mao, Peggy Scherle, Neha Bhagwat, Kris Vaddi, Eric Brooks, Robert A. Baiocchi, Michael B. Jordan, Polina Shindiapina	2024	0
2	Abstract 6270: Combination therapy with selective SMARCA2 (BRM) degraders for treatment of SMARCA4 (BRG1)-deficient cancers Cancer Research ·Michael Hulse, Margot Elkins, Jessica Burtell, Komali Vykuntam, Kris Vaddi, Andrew P. Combs, Koichi Ito, Peggy Scherle	2023	1
3	PRMT5 regulates T cell interferon response and is a target for acute graft-versus-host disease JCI Insight ·Katiri Snyder, Nina C. Zitzer, Yandi Gao, Hannah Choe, Natalie E. Sell, Lotus Neidemire-Colley, Anora Ignaci, Charuta Kale, Raymond D. Devine, Maria G. Abad, Maciej Pietrzak, Min Wang, Hong Lin, Yang W. Zhang, Gregory K. Behbehani, Jane E. Jackman, Ramiro Garzon, Kris Vaddi, Robert A. Baiocchi, Parvathi Ranganathan	2020	27
4	Oral arsenic trioxide ORH-2014 pharmacokinetic and safety profile in patients with advanced hematologic disorders Haematologica ·Farhad Ravandi, Iphigenia L. Koumenis, A. Johri, Martin S. Tallman, Gail J. Roboz, Stephen A. Strickland, Guillermo Garcia‐Manero, Gautam Borthakur, Kiran Naqvi, Meghan Meyer, Madhu Pudipeddi, Sirish Nidarmarthy, Kris Vaddi, Hagop M. Kantarjian	2019	30
5	Ruxolitinib: a targeted treatment option for patients with polycythemia vera SHILAP Revista de lepidopterología ·Kris Vaddi, Srđan Verstovšek, Kiladjian JJ	2016	1
6	A Multi-Institution Phase I Trial of Ruxolitinib in Patients with Chronic Myelomonocytic Leukemia (CMML) Clinical Cancer Research ·Eric Padron, Amy E. DeZern, Marcio Andrade‐Campos, Kris Vaddi, Peggy Scherle, Qing Zhang, Yan Ma, Maria E. Balasis, Sara Tinsley, Hanadi Ramadan, Cassandra Zimmerman, David P. Steensma, Gail J. Roboz, Jeffrey E. Lancet, Alan F. List, Mikkael A. Sekeres, Rami S. Komrokji	2016	62
7	Ruxolitinib: a targeted treatment option for patients with polycythemia vera PubMed ·Lewis-Crofoot Iesha, Kris Vaddi, Srđan Verstovšek, Jean‐Jacques Kiladjian	2016	2
8	Abstract 779: Blockade of the IL-6/JAK/STAT3 signaling pathway inhibits pancreatic tumor cell growth in 3D spheroid cultures and in xenograft models Cancer Research ·Jun Li, Eian Caulder, Margaret Favata, Melody Diamond, Beth Rumberger, Holly K. Koblish, Taisheng Huang, Chu‐Biao Xue, Wenqing Yao, Jordan S. Fridman, Peggy Scherle, Mike Liu, Reid Huber, Kris Vaddi	2015	1
9	Myelofibrosis-associated complications: pathogenesis, clinical manifestations, and effects on outcomes International Journal of General Medicine ·Srđan Verstovšek, Tariq I. Mughal, Kris Vaddi, Nicholas Sarlis	2014	72
10	Preclinical Evaluation of Local JAK1 and JAK2 Inhibition in Cutaneous Inflammation Journal of Investigative Dermatology ·Jordan S. Fridman, Peggy Scherle, Robert J. Collins, Timothy C. Burn, Brett A. Neilan, Denise Hertel, Nancy Contel, Patrick J. Haley, Beth Ann Thomas, Jack Shi, Paul Collier, James D. Rodgers, Stacey Shepard, Brian Metcalf, Gregory Hollis, Robert Newton, Swamy Yeleswaram, Steven Friedman, Kris Vaddi	2011	88
11	INCB16562, a JAK1/2 Selective Inhibitor, Is Efficacious against Multiple Myeloma Cells and Reverses the Protective Effects of Cytokine and Stromal Cell Support Neoplasia ·Jun Li, Margaret Favata, Jennifer Kelley, Eian Caulder, Beth Ann Thomas, Xiaoming Wen, Richard Sparks, Ari Arvanitis, James D. Rogers, Andrew P. Combs, Kris Vaddi, Kimberly A. Solomon, Peggy Scherle, Robert Newton, Jordan S. Fridman	2010	62
12	Safety and Efficacy of INCB018424, a JAK1 and JAK2 Inhibitor, in Myelofibrosis New England Journal of Medicine ·Srđan Verstovšek, Hagop M. Kantarjian, Ruben A. Mesa, Animesh Pardanani, Jörge E. Cortes, Deborah A. Thomas, Zeev Estrov, Jordan S. Fridman, Edward C. Bradley, Susan Erickson‐Viitanen, Kris Vaddi, Richard Levy, Ayalew Tefferi Hit paper breakdown →	2010	847
13	Combined Inhibition of Janus Kinase 1/2 for the Treatment of JAK2V617F-Driven Neoplasms: Selective Effects on Mutant Cells and Improvements in Measures of Disease Severity Clinical Cancer Research ·Phillip C.C. Liu, Eian Caulder, Jun Li, Paul Waeltz, Alex Margulis, Richard Wynn, Mary Becker-Pasha, Yanlong Li, Erin L. Crowgey, Gregory Hollis, Patrick J. Haley, Richard Sparks, Andrew P. Combs, James D. Rodgers, Timothy C. Burn, Kris Vaddi, Jordan S. Fridman	2009	15
14	Abstract #2848: Small molecule inhibitors of JAK1/2 improve physiological and functional measures of cancer-associated cachexia Cancer Research ·Jordan S. Fridman, Eian Caulder, Xiaoming Wen, James D. Rodgers, Andrew P. Combs, Timothy C. Burn, Kris Vaddi	2009	1
15	Conversion of an MMP-potent scaffold to an MMP-selective HER-2 sheddase inhibitor via scaffold hybridization and subtle P1′ permutations Bioorganic & Medicinal Chemistry Letters ·David Burns, Chunhong He, Yanlong Li, Peggy Scherle, Xiangdong Liu, Cindy Marando, Mayanne B. Covington, Gengjie Yang, Max Yu-Chen Pan, Sharon Turner, Jordan S. Fridman, Gregory Hollis, Kris Vaddi, Swamy Yeleswaram, Robert Newton, Steve Friedman, Brian Metcalf, Wenqing Yao	2007	13
16	Pharmacokinetics and Pharmacodynamics of DPC 333 ((2R)-2-((3R)-3-Amino-3{4-[2-methyl-4-quinolinyl) methoxy] phenyl}-2-oxopyrrolidinyl)-N-hydroxy-4-methylpentanamide)), a Potent and Selective Inhibitor of Tumor Necrosis Factor α-Converting Enzyme in Rodents, Dogs, Chimpanzees, and Humans Drug Metabolism and Disposition ·Mingxin Qian, Stephen A. Bai, Bernice L. Brogdon, Jing‐Tao Wu, Rui‐Qin Liu, Maryanne Covington, Kris Vaddi, Robert Newton, Michael J. Fossler, C. Edwin Garner, Yuzhong Deng, Thomas Maduskuie, James M. Trzăskos, James J.‐W. Duan, Carl P. Decicco, David D. Christ	2007	42
17	Selective inhibition of ADAM metalloproteases blocks HER-2 extracellular domain (ECD) cleavage and potentiates the anti-tumor effects of trastuzumab Cancer Biology & Therapy ·Xiangdong Liu, Jordan S. Fridman, Qian Wang, Eian Caulder, Gengjie Yang, Maryanne Covington, Changnian Liu, Cindy Marando, Jin‐Cong Zhuo, Yanlong Li, Wenqing Yao, Kris Vaddi, Robert Newton, Peggy Scherle, Steven Friedman	2006	45
18	CCR2 modulates inflammatory and metabolic effects of high-fat feeding Journal of Clinical Investigation ·Stuart P. Weisberg, Deborah Hunter, Reid Huber, Jacob E. Lemieux, Sarah Slaymaker, Kris Vaddi, Israel Charo, Rudolph L. Leibel, Anthony W. Ferrante Hit paper breakdown →	2005	1226
19	Biology of TACE inhibition Annals of the Rheumatic Diseases ·Robert Newton, Kimberly A. Solomon, Maryanne Covington, Carl P. Decicco, Patrick J. Haley, Steven Friedman, Kris Vaddi	2001	80
20	INCREASED MONOCYTE MCP-1 PRODUCTION IN ACUTE ALCOHOLIC HEPATITIS Cytokine ·Madhav N. Devalaraja, Craig J. McClain, Shirish Barve, Kris Vaddi, Daniell B. Hill	1999	35

About Kris Vaddi

Kris Vaddi is a scholar working on Genetics, Hematology, Oncology, Molecular Biology and Rheumatology, having authored 68 papers that have together received 3.7k indexed citations. Recurring topics across this work include Myeloproliferative Neoplasms: Diagnosis and Treatment (22 papers), Cancer-related gene regulation (19 papers), Acute Myeloid Leukemia Research (10 papers), Cytokine Signaling Pathways and Interactions (9 papers), Chronic Myeloid Leukemia Treatments (7 papers), Eosinophilic Disorders and Syndromes (5 papers), HER2/EGFR in Cancer Research (4 papers) and Cancer Mechanisms and Therapy (4 papers). The work is most often cited by research in Genetics (1.1k citations), Hematology (909 citations), Biological Psychiatry (165 citations), Immunology (739 citations) and Rheumatology (497 citations). Kris Vaddi has collaborated with scholars based in United States, Italy and Qatar. Frequent co-authors include Reid Huber, Stuart P. Weisberg, Jacob E. Lemieux, Sarah Slaymaker, Anthony W. Ferrante, Israel Charo, Deborah Hunter, Rudolph L. Leibel, Jordan S. Fridman and Srđan Verstovšek. Their work appears in journals such as Blood, Cancer Research, Journal of Clinical Oncology, Clinical Cancer Research and Molecular Cancer Therapeutics.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact